Lipoproteins as modulators of atherothrombosis: From endothelial function to primary and secondary coagulation (Q38627278)

4 September 2017

title

Lipoproteins as modulators of atherothrombosis: From endothelial function to primary and secondary coagulation (English)

1 reference

4 September 2017

0 references

2

Miranda Van Eck

1 reference

4 September 2017

Amber B Ouweneel

1

1 reference

4 September 2017

publication date

3 November 2015

1 reference

4 September 2017

published in

Vascular Pharmacology

1 reference

4 September 2017

volume

82

1 reference

4 September 2017

page(s)

1-10

1 reference

Atherosclerosis — An Inflammatory Disease

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Arterial thrombus formation in cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Mechanisms of thrombus formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Coronary Plaque Disruption

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Pathogenesis of acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Pathophysiology of coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Requiem for the 'vulnerable plaque'

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

How does lipid lowering prevent coronary events? New insights from human imaging trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Mechanisms of acute coronary syndromes and their implications for therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Plaque erosion: in vivo diagnosis and treatment guided by optical coherence tomography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Coronary plaque erosion: recognition and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Remodelling of high density lipoproteins by plasma factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Stabilization of atherosclerotic plaques: new mechanisms and clinical targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Long-term predictors of subsequent cardiovascular events with coronary artery disease and 'desirable' levels of plasma total cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Major lipids, apolipoproteins, and risk of vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Macrophages in atherosclerosis: a dynamic balance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Proteome of human plasma very low-density lipoprotein and low-density lipoprotein exhibits a link with coagulation and lipid metabolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Proteomic analysis of high-density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Current perspectives on statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Vastatins Inhibit Tissue Factor in Cultured Human Macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Statin drugs and dietary isoprenoids as antithrombotic agents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Prognostic value of coronary vascular endothelial dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Regulation of endothelial nitric oxide synthase: location, location, location

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Endothelial nitric oxide synthase, caveolae and the development of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Lowering the cholesterol content of MA104 cells inhibits receptor-mediated transport of folate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Extrahepatic high-density lipoprotein receptor SR-BI and apoA-I protect against deep vein thrombosis in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Lipoprotein-induced prostacyclin production in endothelial cells and effects of lipoprotein modification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE-dependent pathway: effects on COX-2/PGI-synthase coupling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Increased Levels of Soluble P-Selectin in Hypercholesterolemic Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Intravascular free tissue factor pathway inhibitor is inversely correlated with HDL cholesterol and postheparin lipoprotein lipase but proportional to apolipoprotein A-II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Subendothelial retention of lipoprotein (a). Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

In vivo induction of endothelial apoptosis leads to vessel thrombosis and endothelial denudation: a clue to the understanding of the mechanisms of thrombotic plaque erosion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

High-density lipoproteins protect endothelial cells from tumor necrosis factor-alpha-induced apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Platelet activation and atherothrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

What causes acute coronary syndromes? Applying Koch's postulates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Antithrombotics in acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

The causal role of megakaryocyte–platelet hyperactivity in acute coronary syndromes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

The effect of hypercholesterolemia on guinea pig platelets, erythrocytes and megakaryocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Altered megakaryocyte-platelet haemostatic axis in hypercholesterolaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Changes in volume and density of platelets in myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Changes in platelet size and count in unstable angina compared to stable angina or non-cardiac chest pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Influence of platelet size on outcome after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Platelet hypersensitivity induced by cholesterol incorporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Increased platelet cholesterol and decreased percentage volume of platelets as a secondary risk factor for coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Increased number of high sensitive platelets in hypercholesterolemia, cardiovascular diseases, and after incubation with cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Platelet function in patients with hypercholesterolaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Increased platelet-fibrinogen interaction in patients with hypercholesterolemia and hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway. Implications for vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

The role of apoE in inhibitory effects of apoE-rich HDL on platelet function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Platelet activation by low density lipoprotein and high density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Binding of low density lipoprotein to platelet apolipoprotein E receptor 2' results in phosphorylation of p38MAPK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

From low-density lipoprotein to platelet activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Oxidation by hypochlorite converts protective HDL into a potent platelet agonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Platelet activation by oxidized low density lipoprotein is mediated by CD36 and scavenger receptor-A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

HDL3 activates phospholipase D in normal but not in glycoprotein IIb/IIIa-deficient platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Bile lipid composition and haemostatic variables in a case of high density lipoprotein deficiency (Tangier disease)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Native high-density lipoproteins inhibit platelet activation via scavenger receptor BI: role of negatively charged phospholipids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Platelet activation by oxidatively modified low density lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Platelet interaction with high and low density lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Rapid activation of human platelets by low concentrations of low-density lipoprotein via phosphatidylinositol cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Reversal by high-density lipoprotein of the effect of oxidized low-density lipoprotein on nitric oxide synthase protein expression in human platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Mechanisms for regulating platelet high density lipoprotein type3 binding sites: evidence that binding sites are downregulated by a protein kinase C-dependent mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

AN ENZYME CASCADE IN THE BLOOD CLOTTING MECHANISM, AND ITS FUNCTION AS A BIOCHEMICAL AMPLIFIER.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

WATERFALL SEQUENCE FOR INTRINSIC BLOOD CLOTTING.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Hypercholesterolemia as a risk factor for deep-vein thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Hyperlipidemia: A novel etiologic factor in deep vein thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Vitamin K-dependent proteins bind to very low-density lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Association between coagulation factors VII and X with triglyceride rich lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Activation of coagulation factor VII during alimentary lipemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Plasma Lipoproteins Support Prothrombinase and Other Procoagulant Enzymatic Complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Binding of prothrombin to chyle chylomicrons: effects of temperature and calcium ions, and role of surface phospholipids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Association of Vitamin K–Dependent Coagulation Proteins and C4b Binding Protein With Triglyceride-Rich Lipoproteins of Human Plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Plasma high density lipoproteins inhibit the activation of coagulation factor X by factor VIIa and tissue factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Effects of lipid-binding proteins apo A-I, apo A-IL, beta 2-glycoprotein I, and C-reactive protein on activation of factor X by tissue factor--factor VIIa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Increased fibrinogen binding to platelets from patients with familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Association between rheology and components of lipoproteins in human blood. Results from the MONICA project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Association between serum fibrinogen concentrations and HDL and LDL subfraction phenotypes in healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Reevaluation of the role of HDL in the anticoagulant activated protein C system in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Re-evaluation of the anticoagulant properties of high-density lipoprotein-brief report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Effects of lipids and lipoproteins on thrombosis and rheology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Statins and LDL-cholesterol lowering: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Blood platelet count and function are related to total and cardiovascular death in apparently healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Safety of CETP inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Effects of dalcetrapib in patients with a recent acute coronary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Potential Signal Transduction Regulation by HDL of the β2-Adrenergic Receptor Pathway. Implications in Selected Pathological Situations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Reconstituted HDL for the acute treatment of acute coronary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Inhibition of arterial thrombus formation by ApoA1 Milano

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Nuclear receptors and lipid physiology: opening the X-files

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Reciprocal regulation of inflammation and lipid metabolism by liver X receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Synthetic LXR ligand inhibits the development of atherosclerosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Identification of macrophage liver X receptors as inhibitors of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

LXR as a novel antithrombotic target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Protein kinase C-dependent desensitization of HDL3-activated phospholipase C in human platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

Platelet and megakaryocyte changes in cholesterol-induced experimental atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VPH.2015.10.009

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VPH.2015.10.009

1 reference

4 September 2017

1 reference